This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-19. (Canceled)

20. (Currently Amended) A hydrophilic controlled release solid tablet ~~oral~~ formulation comprising a matrix comprising, as a substantially homogeneous admixture, about 5% to less than 80%, by weight of the tablet, of pregelatinized starch, an active ingredient that is ~~selected from~~ 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof, and one or more viscous hydrophilic polymers~~, wherein the pregelatinized starch is present in an amount sufficient to enable the formulation to maintain a controlled release of the active ingredient in media of changing ionic strength~~.

21. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 20, wherein said one or more hydrophilic polymers are selected from the group consisting of alkylcellulose, hydroxyalkylcellulose, hydroxyalkylalkylcellulose, carboxyalkylcellulose, alkali metal salts of carboxyalkylcellulose, natural, semi synthetic or synthetic polysaccharide, polyacrylic acid and salts thereof, polymethacrylic acid and the salts thereof, polyvinyl alcohol, polyvinylpyrrolidone, and polyalkylene oxides.

22. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 20, wherein said one or more hydrophilic polymers are selected from the group consisting of hydroxypropyl cellulose and hydroxypropylmethylcellulose.

23. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 22, wherein said hydroxypropylmethylcellulose has a viscosity in a range from about 3,500 mPa.s to about 100,000 mPa.s.

24. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 22, wherein said hydroxypropylcellulose has a viscosity of less than about 1,500 mPa.s.

25. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 20, wherein said one or more hydrophilic polymers are present in an amount from about 0.01 to about 80 % by weight.

26. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 20, wherein at least two hydrophilic polymers are present in said formulation.

27. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 26, wherein said at least two hydrophilic polymers are hydroxypropylcellulose and hydroxypropylmethylcellulose,

28. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 27, wherein a ratio of said hydroxypropylcellulose to said hydroxypropylmethylcellulose ranges from 1:5 to 5:1.

29. (Canceled).

30. (Canceled).

31. (Canceled).

32. (Currently Amended) A method of providing controlled release of 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof, in a subject, comprising administering the controlled release solid tablet ~~oral~~ formulation of claim 20 to said subject.

33. (Currently Amended) A method of preparing a controlled release solid tablet ~~oral~~ formulation comprising ~~a step of~~ mixing 9-hydroxyrisperidone, a pharmaceutically acceptable acid addition salt thereof, an N-oxide form thereof, or a stereochemically isomeric form thereof with about 5% to less than 80%, by weight of the tablet, of pregelatinized starch and one or more hydrophilic polymers, to provide a substantially homogeneous admixture thereof.

34. (Canceled).

35. (Canceled).

36. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 30, wherein said pregelatinized starch is present at about 5% (w/w).

37. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation of claim 20[[30]], wherein said pregelatinized starch is present at about 5% to about 15%, by weight of the tablet [[(w/w)]].

38. (Canceled)

39. (Currently Amended) The controlled release solid tablet ~~oral~~ formulation according to any one of claims 20 to 28[[, 30,]] or [[35]] 36 to 37[[38]] wherein the ~~in the form of a~~ tablet consists~~consisting~~ essentially of an optional coating and a controlled release matrix comprising a substantially homogeneous admixture comprising said active ingredient, said one or more viscous hydrophilic polymers, and said pregelatinized starch.